Company intelligence / Profile preview

Stradefy Biosciences

New Haven, Connecticut, United Statesstradefybio.com ↗

Ownership: Private
Development stage: Other

Overview

Stradefy’s lead candidate has shown efficacy in multiple oncology models. The company is progressing toward IND filing with a capital-efficient strategy. Their BDC platform demonstrates improved retention, internalization, and therapeutic payload delivery compared to antibody-drug conjugates. No clinical trial results yet as programs are preclinical/IND-enabling.

Therapeutic areas: ImmunologyOncologyOther
Modalities: NanoparticlePolymer nanoparticleBioadhesive drug carrier (BDC)Small molecule (as payloads within BDCs)
Industry: Biotech

Partnerships

Yale University (technology licensed from Yale labs)Elm Street Ventures (lead investor/supporter)

Beyond the preview

Go deeper on Stradefy Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stradefy Biosciences.

Explore the full profile